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Background. In acute coronary syndrome (ACS), inflammation and redox response are associated with increased residual platelet
reactivity (RPR) on clopidogrel therapy. We investigated whether clopidogrel interaction affects platelet function and modulates
factors related to inflammation and oxidation in ACS patients differently responding to clopidogrel.Material andMethods. Platelet
aggregation was measured in 29 ACS patients on dual (aspirin/clopidogrel) antiplatelet therapy. Nonresponders (NR) were defined
as RPR ≥70% by ADP. Several inflammatory and redox parameters were assayed and platelet proteome was determined. Results.
Eight (28%) out of 29 ACS patients resulted NR to clopidogrel. At 24 hours, the levels ofTh2-type cytokines IL-4, IFN𝛾, andMCP-1
were higher in NR, while blood GSH (r-GSHbl) levels were lower in NR than responders (R). Proteomic analysis evidenced an
upregulated level of platelet adhesion molecule, CD226, and a downregulation of the antioxidant peroxiredoxin-4. In R patients
the proinflammatory cytokine IL-6 decreased, while the anti-inflammatory cytokine IL-1Ra increased. Conclusions. In patients with
high RPR on clopidogrel therapy, an unbalance of inflammatory factors, platelet adhesion molecules, and circulatory and platelet
antioxidantmolecules was observed during the acute phase. Proinflammatorymilieu persists in nonresponders for a long time after
the acute event while antioxidant blood factors tend to conform to normal responsiveness.
1. Introduction
Since platelet activation plays a critical point in the patho-
genesis of ACS [1], antiplatelet treatments are frequently used
in patients with acute coronary syndrome (ACS), in order
to reduce ischemic events. The dual antiplatelet therapy that
combines aspirin (acetylsalicylic acid, ASA) and a platelet
P2Y
12
receptor inhibitor is the standard antithrombotic
strategy in the treatment of ACS and for the prevention
of thrombotic complications subsequent to percutaneous
coronary intervention (PCI) [2]. Despite the availability of
newer platelet P2Y
12
receptor inhibitors, clopidogrel remains
widely used, also because it allows a considerable cost-
containment. However, notwithstanding significant benefits
reported with dual antiplatelet treatment inmajor clinical tri-
als, the occurrence of major ischemic events, including stent
thrombosis, remains a serious clinical problem [3]. Several
studies have revealed variability of antiplatelet efficacy based
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on the so-called “clopidogrel resistance” [4–6]. Lack of ade-
quate platelet inhibition to clopidogrel might be associated
with many factors including patient noncompliance, drug
interactions, alternative mechanisms of platelet activation,
metabolic pathway alterations, and also polymorphisms of
genes that play a role in clopidogrel metabolism [7, 8].
Inflammation plays an important role in the patho-
physiology and prognosis of ACS. The extent of inflamma-
tory response is crucial in haemostatic system, throughout
increased platelet reactivity and endothelial dysfunction,
factors which are potentially involved in the variability of
antiplatelet efficacy [9]. In this context, elevated leuko-
cyte count and high levels of anti-inflammatory cytokine
interleukin- (IL-) 10 are reported as important factors asso-
ciated with the probability of low clopidogrel responsive-
ness [10]. Differently, an inverse relationship between anti-
inflammatory cytokine IL-4 and the residual platelet reactiv-
ity was reported in ACS patients on dual antiplatelet therapy
[11], suggesting a complex interaction between inflammatory
pathways and response to clopidogrel.
Experimental and clinical studies suggest also a pivotal
role of reactive oxidant species (ROS) in the mechanism of
platelet activation [12]. ROS are implicated in platelet activa-
tion by inactivating nitric oxide (NO) and releasing platelet
agonists and proatherogenic molecules [12]. In particular,
the main antioxidant amino-thiol glutathione (GSH) has a
central role in the redox modulation of platelet activity [13],
and it is known that deficiencies of enzymes that are involved
in GSH synthesis are associated with cardiovascular events
[14]. Moreover, in human platelets, NO pathway is a target
of the prooxidant amino-thiol homocysteine (Hcy), which
promotes the reduction of NO, platelet hyperactivation, and
other thrombogenic processes [15, 16].
More recently, with the omics booming, proteomics
approaches have been often adopted to investigate platelet
proteome. In a previous proteomics study it was reported that
ASA-resistant patients show an increased plasma expression
of vitamin D-binding protein isotypes [17]. This was associ-
ated with the failure of ASA to prevent both thromboxane
A2 production and platelet activation, unmasking a potential
mechanism involved in ASA resistance. Moreover, platelet
protein profiling of patients with stable angina under clopido-
grel therapy shows different expression of proteins involved in
the cytoskeleton rearrangement, in the energeticmetabolism,
and in the oxidative stress [18].
The aim of this study was to associate several soluble
circulating inflammatory markers and redox factors in ACS
patients with different responses to clopidogrel treatment.
In a restricted subgroup of patients [6], mass spectrometry-
based protein profile of platelet proteome was investigated
and information on oxidative, inflammatory pathways and
energetic metabolism was obtained.
2. Material and Methods
2.1. Population Enrolment and Platelet Reactivity Assessment.
Twenty-nine ACS patients undergoing PCI, stent implan-
tation in dual antiplatelet therapy with clopidogrel, and
ASA were enrolled at the University Hospital of Careggi in
Florence. Platelet reactivity assessment was made by light
transmittance aggregometry (APACT4, Helena Laboratories,
Milan, Italy) using adenosine diphosphate (ADP) as an ago-
nist [19]. Blood samples anticoagulated with 0.109M sodium
citrate (ratio, 9 : 1) were obtained 24 hours, 1 week, and 1
month after a 600 mg clopidogrel loading dose. Platelet-rich
plasma, obtained by centrifuging whole blood for 10 minutes
at 200 g, was stimulated with 10 𝜇M ADP. The 100% line was
set using platelet-poor plasma and the 0 baseline established
with platelet-rich plasma (adjusted from 180 × 109/L to 300 ×
109/L). Platelet aggregation (according to the Born method)
was evaluated considering the maximal percentage of platelet
aggregation in response to stimulus. Runs of 10 minutes were
set for all the agonists used in the LTA test in order to
better characterize the profile of aggregation/disaggregation.
Maximum aggregation was used in order to measure the
entity of platelet inhibition. The coefficient of variation of
ADP platelet aggregation was 6.8%. Platelet reactivity was
evaluated within 24 hours from clopidogrel loading. High
residual platelet reactivity by ADP test was defined as platelet
aggregation of 70% or greater [20].
The study complied with the principles of the Decla-
ration of Helsinki, and Careggi Hospital Ethics Committee
approved the study protocol. All the patients gave written
informed consent to participate in the study. Patients with
poor adherence to the prescribed therapywere excluded from
the study.
2.2. Assessment of Inflammatory Parameters. In all enrolled
ACS patients, blood (Na2+-EDTA and 4% trisodium citrate
as anticoagulants) samples were collected at 24 hours, 1 week,
and 1 month from administration of dual antiplatelet therapy
for the assessment of a panel of inflammatory mediators,
consisting of cytokines associated with Th1/Th2-type T cells
(interleukin- (IL-) 4, IL-12, and interferon-gamma (IFN-𝛾)),
pro- (IL-6 and tumor necrosis factor alpha (TNF-𝛼)), and
anti-inflammatory cytokines (IL-10 and receptor antagonist
of IL-1 (IL-1ra)), and chemotactic molecules (interferon-
gamma-induced protein 10 (IP-10 or CXCL10), interferon-
inducible T cell alpha chemoattractant (I-TAC or CXCL11),
monocyte chemotactic protein-1 (MCP-1), and macrophage
inflammatory protein-1𝛽 (MIP-1𝛽 or CCL4)).
Plasma inflammatorymediators were determined by Bio-
Plex cytokine assay (R&D Systems, Minneapolis, MN, USA)
according to manufacturer’s instructions.
2.3. Assessment of Redox Status. In 23 out of 29 enrolled ACS
patients, additional blood samples were collected at 24 hours,
1 week, and 1 month after administration of dual antiplatelet
therapy for the assessment also of reduced and total aminoth-
iols, Hcy, and GSH, and the activities of GSH peroxidase
type-1 (GPx-1). Blood reduced GSH (r-GSHbl) level was
determined by prompt acidification of whole blood imme-
diately after blood sample collection according to method
previously described [14]. As reduced GSH levels in plasma
are low (1-2%), the reduced GSH concentration in whole
blood can reflect GSH content inside the cellular fraction of
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Figure 1: Flow cytometric determination of white blood cell (WBC) contamination of platelet suspensions. Flow cytometric analysis after
staining with antibodies specific for CD61 (PerCP-Cy5-5) and for CD45 (APC-Cy7). In (a), the box includes cellular suspension according to
SSC and FSC. In (b) the CD61+/CD45+ events gated on P1 are shown in the right upper quadrant.
blood. Plasma reduced and total forms of Hcy and blood total
GSHwere determined according to methods validated in our
laboratory [14].The total form of GSHmeasured in our study
includes the oxidized GSH, all conjugated forms of GSH
(protein-bound GSH and GSH-mixed disulfides), produced
through oxidative processes or thiol-disulfide exchange reac-
tions, and reduced free GSH.Thiol separation was performed
by high-performance liquid chromatography (HPLC)
method (ProStar-Varian, Surrey, UK). Erythrocyte GPx-1 was
determined using t-butyl hydroperoxide (SIGMA, Steinheim,
Germany) as substrate [21]. GPx-1 activities were determined
in diluted purified red blood cells, stored frozen up to
analysis which was performed within 1 month from storage.
2.4. Platelet Isolation, Protein Extraction, Reduction, Alkyla-
tion, and Digestion. In a restricted population of 12 ACS
patients (6 nonresponders), platelet-rich plasma (PRP) was
obtained from whole blood at 24 hours after administration
of dual antiplatelet therapy. PRP was prepared by centrifug-
ing blood samples at 150 g for 10 minutes. Then it was
removed and platelet-poor plasma was prepared by further
centrifugation at 3,000 g for 3 minutes. PRP was adjusted
with autologous platelet-free plasma to reach a platelet count
between 180000 plt/𝜇L and 300,000 plt/𝜇L. The purity of
isolated platelets was confirmed by flow cytometry on a
Becton Dickinson FACS can instrument.
White blood cells in platelet suspension were identified
through their expression of CD45. A volume of 10 𝜇L of
platelet suspension was incubated for 20min in the dark with
(1) peridinin chlorophyll protein-cyanin-5.5- (PerCP-Cy5.5-)
labelledmonoclonal antibodies against humanCD61 (Becton
Dickinson, San Jose, USA); (2) allophycocyanin-cyanin-7-
(APC-Cy7-) labelled monoclonal antibodies against human
CD45 (Becton Dickinson, San Jose, USA) (Figure 1).
PRP samples were centrifuged at 800 g for 15min and pel-
lets of platelets were resuspended in 350 𝜇L of lysis solution
(Tris/HCl 50mM, 0.1%Triton-X100).Detergentwas removed
using detergent removal columns (Pierce) following manu-
facturer instructions. Briefly, protein extracts were placed on
the column and incubated for two minutes. Columns were
centrifuged for twominutes to collect detergent-free samples.
BCA assay was used to evaluate total protein concentration.
100 𝜇L of protein extract (1 𝜇g/𝜇L concentration) was added
to 100 𝜇L of 40mM of ammonium hydrogen carbonate
(pH = 8). Reduction was obtained by adding 1 𝜇L of 1M
dithiothreitol to each sample, with an incubation of 20min
at 80∘C. For alkylation, 20𝜇L of 100mM iodoacetamide was
added to the samples and incubated for 30min at 37∘C.
Trypsin digestion was performed incubating samples with
8microL of 0.25mg/ml solution at 37∘C overnight.
2.5. LC-MS/MS Analysis. Chromatographic separation of
peptides was performed using an ultimate 3000 nano-HPLC
system (LC Packings, DIONEX, USA). 100 𝜇L of sample was
added to a solution composed by 2%CH
3
CNand 0.1% formic
acid up to 200𝜇L of final volume. The loading pump pre-
concentrated the sample in a precolumn cartridge (PepMap-
100 C18 5mm 100A, 30mm id × 5mm). Chromatographic
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separation of peptides was performed using a C18 PepMap-
100 column (15 cm× 75mm id, LCPackingsDIONEX) equili-
brated at 45∘Cwith solvent A (water/acetonitrile 98/2 vol/vol,
0.1% formic acid) at a flow rate of 300 nLmin−1. Runs were
performed under 40min linear gradient from 10 to 45%
of solvent B (water/CH
3
CN 2/98 vol/vol, 0.1% formic acid)
followed by 10min of a purge step at 95% of B before a 20min
reequilibration step to the starting conditions. The column
was directly coupled to TripleTOF 5600 System (AB SCIEX,
Toronto, Canada), equipped with a DuoSpray ion source (AB
SCIEX, Toronto, Canada). Eluted peptides were directly pro-
cessed using TripleTOF 5600 mass spectrometer (AB SCIEX,
Toronto, Canada). The mass spectrometer was controlled by
Analyst 1.6.1 software (AB SCIEX, Toronto, Canada). For
positive ionization, ion source parameters were the following:
spray voltage 3KV, temperature 150∘C, curtain gas 25 psi, GS1
10 psi. For information dependent acquisition (IDA) analysis,
survey scans were acquired in 250ms. Dynamic exclusion
was set for 1/2 of peak width (∼8 s), and then the precursor
was refreshed off the exclusion list.
2.6. Protein Identification and Label-Free Comparative Analy-
sis. MS/MS data were processed with ProteinPilot Software
(AB SCIEX, Toronto, Canada), using the Paragon and Pro
Group Algorithms and SwissProt 2013 as protein database for
Homo sapiens species. The false discovery rate analysis was
done using the integrated tools in ProteinPilot software and
a confidence level of 95% was set. The statistical comparative
analysis was performed usingMarkerView Software 1.2.1 (AB
SCIEX).The ion chromatograms of high confidence peptides
identified by ProteinPilot were extracted using PeakView
Software and then MS peak areas and identifications were
imported into MarkerView Software.
2.7. Statistical Analysis. Continuous variables were presented
as median and interquartile ranges and categorical data
as frequency (%). Group comparisons (responders versus
nonresponders) of the clinical and biochemical character-
izations were performed by unpaired Student’s 𝑡-test for
continuous variables or Mann-Whitney 𝑈 test for not nor-
mally distributed variables, and Chi-square or Fisher’s exact
test for categorical variables. Time-dependent changes (24
hours, 1 week, and 1 month) in groups were assessed by
nonparametric Friedman test (𝑃 for time); pairwise post hoc
comparisons were performed by using the Wilcoxon signed-
rank test with Bonferroni correction.
Pearson’s correlation coefficient (𝑟) and the equivalent
nonparametric Spearman’s rho (rho) correlation coefficient
were used to analyze the association between biochemical
variables.
For mass spectrometric data, principal component anal-
ysis (PCA) was performed with MarkerView 1.2 software in
order to evidence groupings among the data set. All profile
areas were normalized using total area sum. The two groups
(responders (R) and nonresponders (NR)) were compared
with 𝑡-test with a threshold of 95% (𝑃 value = 0.05) and
fold change > 2. A 𝑃 value <0.05 was considered statistically
significant.
3. Results
3.1. Clinical Characteristics of Clopidogrel Nonresponder and
Responder Patients. Themedian age of enrolled ACS patients
was 75 (71–98) years. For sixteen (55%) patients ST-segment
elevation myocardial infarction was characterized by electro-
cardiography, and 8 (28%) patients showed three-vessel coro-
nary artery disease. Eight (28%) out of 29 ACS patients were
considered NR to clopidogrel. The clinical characteristics of
R and NR patients are summarised in Table 1.
The main clinical features of R and NR patients were
similar, with exception of bare metal coronary stents and
diabetes that were more frequent in NR patients.Themedical
history was comparable too, as well as therapy (in particular
the administration of GPIIb/IIIa inhibitors) associated with
clopidogrel-based antiplatelet treatment (Table 1).
3.2. Inflammatory and Redox Patterns in Clopidogrel Nonre-
sponder and Responder Patients during Early Phases of Dual
Antiplatelet Treatment. The inflammatory data concerning
the acute phase of ACS at 24 hours after clopidogrel loading
dose are reported in Table 2.
NR patients showed higher levels of IL-4 and IFN𝛾 that
are both associated with the differentiation of naive T cellTh1
andTh2.The levels of anti-inflammatory cytokine IL-10 were
higher in NR than in R, while the levels of proinflammatory
cytokines, IL-6 andTNF 𝛼, were comparable between the two
groups. Among chemokines, MIP-1𝛽 was more concentrated
in NR platelets, while I-TAC was present in higher levels in R
patients.
Among inflammatory variables, in all patients, IL-4 levels
were positively related only with MIP-1𝛽 levels (rho = 0.56,
𝑃 = 0.008), while, in NR patients, MIP-1𝛽 levels were related
with IL-10 levels (rho = 0.93, 𝑃 = 0.001).
The redox data associated with clopidogrel resistance
during the acute phase of ACS at 24 hours after clopidogrel
loading dose are summarized in Table 3.
The levels of aminothiols, in both plasma and whole
blood, were equivalent in the two patient groups, with the
exception of the r-GSHbl, whichwas significantly lower inNR
and positively related with plasma total GSH levels (rho =
0.51, 𝑃 = 0.014). GPx-1 activities were also comparable
between groups.
Among all patients, IL-4 levels were negatively related
to plasma reduced GSH (rho = −0.59, 𝑃 = 0.004) and
TNF-𝛼 levels were negatively associated with r-GSHbl (rho =
−0.52, 𝑃 = 0.016). Differently, I-TAC levels were positively
correlated to plasma reduced GSH (rho = 0.56, 𝑃 = 0.008).
3.3. Inflammatory and Redox Profiles in Responders and Non-
responders. Follow-up evaluation of inflammatory and redox
profiles was assessed in 19 ACS patients (24 hours, one week,
and one month after clopidogrel loading dose). In NR, the
levels of inflammatory parameters were unchanged during
the first month after dual antiplatelet therapy administration,
with the exception of IL-6 that tended to decrease after one
week from the acute phase. At variance, R patients showed
Mediators of Inflammation 5
Table 1: Clinical characteristics between clopidogrel-responder and -nonresponder patients.
Responders (𝑛 = 21) Nonresponders (𝑛 = 8) 𝑃
Age, years 73 (60–80) 78 (71–83) 0.341
Male, 𝑛 (%) 15 (71) 4 (50) 0.242
BMI, kg/m2 25 (23–27) 26 (24–31) 0.241
STEMI, 𝑛 (%) 11 (52) 5 (63) 0.697
NSTEMI, 𝑛 (%) 10 (48) 3 (37) 0.697
Lesion coronary artery, 𝑛 2 (1–3) 1 (1-2) 0.189
Three-vessel coronary artery disease, 𝑛 (%) 7 (33) 1 (13) 0.381
Killip class, 𝑛 (%) 0.804
0 2 (10) 1 (13)
1 17 (85) 7 (88)
2 1 (5) 0 (0)
Stent implantation, 𝑛 (%)
DES 11 (52) 1 (13) 0.093
BMS 9 (43) 8 (100) 0.009
Risk factors, 𝑛 (%)
Smoking 8 (38) 1 (13) 0.371
Hypertension 13 (62) 5 (63) 1.000
Hyperlipidemia 4 (19) 3 (38) 0.357
Diabetes mellitus 3 (14) 5 (63) 0.019
Family history of CAD 1 (5) 1 (13) 0.483
Medical history, 𝑛 (%)
PCI 1 (5) 1 (13) 0.483
CABG 0 (0) 1 (13) 0.276
LEAD 2 (10) 0 (0) 1.000
Ictus 0 (0) 0 (0) —
Renal failure 1 (5) 0 (0) 1.000
Atrial fibrillation 2 (10) 1 (13) 1.000
COPD 2 (10) 1 (13) 1.000
Medical therapy, 𝑛 (%)
Ca-antagonist 3 (14) 1 (13) 1.000
Ca-channel blockers 0 (0) 0 (0) —
ACEi 13 (62) 4 (50) 0.683
ARB 2 (10) 1 (13) 1.000
𝛽-blockers 10 (48) 5 (63) 0.682
Statins 21 (100) 8 (100) —
GPIIb/IIIa inhibitors 7 (33) 3 (38) 1.000
Data are expressed as median and interquartile range (25th–75th) or number (percentage).
ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blockers; BMI: body mass index; Ca: calcium; BMS: bare metal coronary stent;
CABG: coronary artery by-pass grafting; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; DES: drug-eluting stent; LEAD: lower
extremity arterial disease; GP: glycoprotein; PCI: percutaneous coronary intervention; NSTEMI; non-ST-segment elevation myocardial infarction.
significant changes of IL-6, IL-1ra, and IL-4 levels over time
(Figure 2).
In particular, a reduction of IL-6 levels was observed
in R patients (Figure 2(a)) resulting lower one month after
treatment than in NR patients [0.6 (0.0–6.1) and 11.3 (3.3–
54.6) pg/mL of IL-6 in R and NR patients, respectively 𝑃 =
0.059]. Differently, an increment of the IL-1ra levels was
observed at one week in Rwith respect to NR patients (Figure
2(b)). In addition, responders showed a significant increase
of IL-4 levels one week after treatment, returning to baseline
values at one month (Figure 2(c)). The levels of chemotactic
molecules did not change over time in both groups with
respect to those observed in the acute phase (Table 4).
Among redox variables, NR patients showed significant
changes with respect to R patients of the r-GSHbl levels,
which tended to reequilibrate after one month (Figure 3(a)).
Likewise, the levels of blood total GSH (t-GSHbl) were
reduced one week after dual antiplatelet therapy administra-
tion (Figure 3(b)). In NR, the activity of GPx-1 reached an
activity comparable to that of R patients within one week
(Figure 3(c)). The levels of Hcy did not change over time in
both groups as compared to the acute phase (Table 4).
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Table 2: Inflammatory pattern at 24 hours from daily administration of dual antiplatelet treatment in clopidogrel responders and
nonresponders.
All cases (𝑛 = 29) Responders (𝑛 = 21) Nonresponders (𝑛 = 8) 𝑃
Th1/Th2 milieu
IL-4, pg/mL 0.66 (0.27–1.28) 0.57 (0–0.76) 1.28 (0.84–4.67) 0.003
IL-12, pg/mL 69.1 (44.1–106.2) 59.5 (36.5–101.6) 91.4 (63.0–119.7) 0.106
IFN𝛾, pg/mL 63.2 (49.4–99.1) 55.2 (43.9–88.5) 93.1 (60.2–127.3) 0.066
Proinflammatory cytokines
IL-6, pg/mL 5.7 (3.2–19.9) 5.1 (3.2–20.0) 9.7 (3.5–1406.4) 0.381
TNF-𝛼, pg/mL 2.9 (0.7–10.9) 2.4 (0–5.5) 9.4 (0.8–23.2) 0.283
Anti-inflammatory cytokines
IL-1ra, pg/mL 750 (595–1222) 713 (563–1093) 1005 (675–2686) 0.218
IL-10, pg/mL 25.4 (13.1–34.5) 20.3 (11.2–28.7) 32.2 (25.7–38.3) 0.079
Chemokines
I-TAC, pg/mL 165 (69–206) 177 (162–228) 74 (0–170) 0.080
IP10, pg/mL 965 (726–2200) 949 (726–2223) 1532 (698–2118) 0.897
MCP-1, pg/mL 17.3 (14.9–31.8) 17.3 (14.8–31.8) 21.1 (15.0–31.3) 0.775
MIP-1𝛽, pg/mL 94.5 (66.7–115.1) 78.1 (58.2–108.4) 115.3 (96.3–131.3) 0.016
Data are expressed as median and interquartile range (25th–75th).
IL: interleukin; IFN: interferon; IP10: interferon-gamma-induced protein 10; I-TAC: interferon-inducible T cell alpha chemoattractant; MCP-1: monocyte
chemotactic protein-1; MIP-1𝛽: macrophage inflammatory protein-1𝛽; TNF: tumor necrosis factor; Th1/Th2: T helper type-1 or type-2 cells.
Table 3: Redox status at 24 hours fromdaily administration of dual antiplatelet treatment between clopidogrel responders and nonresponders.
All cases (𝑛 = 23) Responders (𝑛 = 17) Nonresponders (𝑛 = 6) 𝑃
r-Hcypl, 𝜇mol/L 0.19 (0.14–0.20) 0.20 (0.15–0.25) 0.17 (0.10–0.19) 0.227
t-Hcypl, 𝜇mol/L 13.5 (8.6–15.3) 13.0 (8.6–15.2) 13.9 (9.8–16.6) 0.812
r-GSHpl, 𝜇mol/L 3.93 (1.64–5.59) 4.25 (1.54–6.24) 3.52 (1.71–4.50) 0.412
t-GSHpl, 𝜇mol/L 6.10 (2.78–7.08) 6.26 (3.46–7.08) 3.84 (2.60–7.46) 0.560
r-GSHbl, 𝜇mol/L 426 (393–500) 451 (410–537) 392 (315–431) 0.033
t-GSHbl, 𝜇mol/L 998 (784–1099) 1031 (876–1108) 873 (716–1054) 0.294
GPx-1, IU/grHb 12.8 (9.3–17.8) 12.6 (9.3–13.4) 19.5 (8.7–27.5) 0.203
Data are expressed as median and interquartile range (25th–75th).
Bl: blood; GSH: glutathione; GPx-1: glutathione peroxidase type-1; GPx-3: glutathione peroxidase type-3; pl: plasma; r: reduced; t: total.
3.4. Proteomics Analysis of Clopidogrel Responders and Non-
responders. The platelet proteome of 12 ACS patients (6
R and 6 NR) was analyzed by LC-MSMS approach 24
hours after clopidogrel loading dose. Individual profiles were
obtained in 1 hour of chromatographic separation coupled
with electrospray mass spectrometry. 74 proteins related to
inflammation, oxidative state, and energeticmetabolismwere
identified with a Protein Score (Confidence) > 95% and using
local false discovery rate analysis >1% as stringent criterion to
avoid false positives (Figure 4).
Differentially expressed markers were evaluated using
MarkerView software, and 3 proteins (CD226, peroxire-
doxin-4 (PRDX4), and transferrin (TRFE)) were differently
modulated between R and NR patients (Figures 5(a)–5(c)).
4. Discussion
In the present study, changes in expression and modulation
of inflammation, redox, and platelet molecules were investi-
gated in R andNR to clopidogrel-based antiplatelet treatment
patients during ACS. In the acute phase of the coronary syn-
drome, the IL-4 and MIP-1𝛽 levels were found higher in NR
than inR patients. IL-4, a knownTh2-type anti-inflammatory
cytokine, is crucial to modulate T cell differentiation and
to direct differentiation of human monocytes into antigen
presenting specialized cells [21]. The T cell differentiation
into Th1 or Th2 is important in the clinical context of ACS
since Th1 cells are able to activate monocytes/macrophages,
committing them to the so-called “delayed-type hypersen-
sitivity” phenomenon [22], and to induce the expression of
factors promoting microthrombosis. Gori et al. [11] reported
an inverse relationship between levels of IL-4 and the residual
platelet reactivity in ACS patients undergoing PCI on dual
antiplatelet therapy. In our study, NR patients showed higher
levels of peripheral IL-4, data which seem to exclude a T cell
differentiation towards the Th1 profile.
MIP-1𝛽 is known as CCR5 macrophage receptor ligand,
involved in the activating signals for the monocyte recruit-
ment during atherogenesis and in inflammatory processes
[23]. Currently, the involvement of MIP-1𝛽 and CCR5 signals
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Table 4: Time-dependent changes of Hcy and chemotactic molecules levels.
Responders Nonresponders
24 hours 1 week 1 month 𝑃 24 hours 1 week 1 month 𝑃
r-Hcypl, 𝜇mol/L 0.20 (0.15–0.25) 0.20 (0.14–0.20) 0.20 (0.15–0.30) 0.307 0.17 (0.10–0.19) 0.18 (0.12–0.22) 0.21 (0.12–4.48) 0.050
t-Hcypl, 𝜇mol/L 13.0 (8.6–15.2) 12.1 (10.9–14.6) 12.1 (10.4–15.7) 0.936 13.9 (9.8–16.6) 11.6 (9.4–13.2) 12.3 (9.9–36.2) 0.368
I-TAC, pg/mL 177 (162–228) 207 (88–292) 187 (89–268) 0.144 74 (0–170) 76 (0–202) 32 (0–224) 0.223
IP10, pg/mL 949 (726–2223) 986 (817–1317) 1060 (765–1550) 0.344 1532 (698–2118) 1135 (877–2764) 1122 (941–2751) 0.819
MCP-1, pg/mL 17.3 (14.8–31.8) 19.5 (11.0–24.5) 19.5 (15.5–31.1) 0.420 21.1 (15.0–31.3) 41.7 (20.1–50.3) 28.1 (15.4–31.8) 0.819
MIP-1𝛽, pg/mL 78.1 (58.2–108.4) 65.7 (50.1–108.7) 75.4 (45.5–94.0) 0.549 115.3 (96.3–131.3) 99.1 (84.8–120.9) 124.6 (72.2–140.8) 0.549
Data are expressed as median and interquartile range (25th–75th).
pl: plasma; r: reduced; t: total; I-TAC: interferon-inducible T cell alpha chemoattractant; MCP-1: monocyte chemotactic protein-1; MIP-1𝛽: macrophage
inflammatory protein-1𝛽; TNF: tumor necrosis factor; Th1/Th2: T helper type 1 or type 2 cells.
𝑃: time-dependent changes (24 hours, 1 week, and 1 month) in groups assessed by nonparametric Friedman test.
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Figure 2: Profile of levels of IL-6 (a), IL-1ra (b), and IL-4 (c) in NR and R patients (R: empty box-plots; NR: dark box-plots). 𝑃 for time refers
to time-dependent changes (24 hours, 1 week, and 1 month) in groups assessed by nonparametric Friedman test, ∗𝑃 < 0.025 versus 24 hrs by
Bonferroni adjusted post hoc test for pairwise comparisons.
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NR: dark box-plots). 𝑃 for time refers to time-dependent changes (24 hours, 1 week, and 1 month) in groups assessed by nonparametric
Friedman test.
in response to antiplatelet therapy in ACS patients is poorly
understood. In our study, the circulating levels of MIP-1𝛽
were found higher in NR than in R patients suggesting a
greater tendency for the recruitment of monocytes. Likewise,
few data are available regarding chemokine (C-X-C motif)
receptor 3 (CXCR3) in response to antiplatelet therapy in
ACS patients. CXCR3 receptor, preferentially expressed on
activated Th1-cell population, is known to be involved in
the recruitment of circulating activated immune cells [24].
CXCR3 receptor is activated by IFN-𝛾-inducible chemokines
such as CXCL9, CXCL10 (IP-10), and CXCL11 (I-TAC), which
are highly expressed in atherosclerotic lesions and play an
important role inTh1-cell homing. Gori et al. reported higher
levels of IP-10 in ACS patients on dual antiplatelet therapy
with residual platelet reactivity, characterized also by elevated
levels of IFN-𝛾 with respect to R patients [11]. In our NR
patients, despite confirmed higher levels of IFN-𝛾, circulating
levels of I-TAC were lower. Altogether, these data support an
involvement of CXCR3-binding chemokines in response to
clopidogrel-based therapy in ACS patients, even if these data
are not conclusive.
Of note, the levels of proinflammatory cytokine IL-6
decreased significantly only in R patients over time while the
levels of anti-inflammatory cytokine IL-1ra are maintained
elevated. These results suggest the presence of a more bal-
anced inflammatory milieu in R with respect to NR patients;
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Figure 5: Platelet protein expression of CD226 (a), PRDX4 (b), and transferrin (c) in NR and R patients (R: empty box-plots; NR: dark
box-plots).
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this impression is furthermore reinforced by elevated levels of
IL-6 and MIP-1𝛽, also persisting after one month from acute
event.
In our study, the analysis of redox pattern has evidenced
significantly lower levels of r-GSHbl in the acute phase of NR
compared to R patients. These data support the hypothesis
that NR patients, during the acute phase, also present GSH
depletion in addition to altered IL-4 and MIP-1𝛽 levels.
Several studies suggest a critical role of ROS andof lowmolec-
ular weight thiols, such as GSH, in modulation of platelet
activation [25, 26]. In particular, in type-2 diabetes, the
platelet hyperreactivity appears to be due to both deficiency of
intraplatelet antioxidant status and reduced bioavailability of
antithrombotic NO [27]. In ACS patients, the GSH-defective
redoxmilieumight reflect a condition of oxidative stress or an
increased production of ROS contributing to residual platelet
reactivity. These findings are consistent with recent data by
Becatti et al. [28] showing that ROS production is strictly
correlated to the platelet aggregation and can be predictor of
poor responsiveness to dual antiplatelet treatment.Moreover,
the inverse correlations between the levels of GSHbl and
inflammatory parameters, such as IL-4 and I-TAC levels,
suggest that the redox pattern, GSH-defective, might also
affect the inflammatory pathway in ACS patients. Unlike
the inflammatory state, the redox status in NR varies over
time during therapy reaching the levels of the R patients (in
particular the blood reduced GSH level and GPx-1 activity).
This phenomenon might reflect a persistent action of the
antioxidant system against oxidative stress. Nevertheless, the
persistence of a greater inflammation in NR patients over
time during antiplatelet therapy supports a more crucial role
of the inflammation than redox state in response to clopido-
grel.
Even analyzing the protein profile of platelets in a
limited cohort of patients, the differential modulation of
specific inflammatory and redox signals, in platelets of
patients presenting different response to antiplatelet therapy,
is confirmed and other involved markers are evidenced.
CD226, a platelet adhesion molecule, is found overexpressed
in platelet proteome of R patients [29]. In NR patients,
the upregulation of platelet CD226 and the elevated levels
of plasma MIP-1𝛽 highlight the presence of inflammatory
mechanisms that promote adhesion of platelets and mono-
cytes to vascular endothelial cells. Otherwise, the levels of
PRDX4, an antioxidant enzyme crucial for the detoxification
of hydrogen peroxide and superoxide, are reduced in NR
patients. Accordingly, decreased platelet antioxidant content
is known to be related to increased platelet aggregation
[30]. TRFE minimizes the ability of circulating free iron to
catalyze formation of free radicals. Indeed, TRFE levels are
found reduced in patients with acute ischemic stroke, in
conjunction with reduced values of the antioxidants GSH
and GPx [31, 32]; furthermore, also thiols can reduce TRFE
generating an increase of oxygen-derived free radicals [33].
Additionally, in presence of TRFE, a significant increase in
lipid and protein oxidation and a decrease in GSH levels were
observed in platelets [34]. Therefore, the different expression
of PRDX4 and TRFE between R and NR and the low levels of
blood GSH inNR highlight the role of redox-sensitive signals
on platelet and the importance that these molecules could
have in the effectiveness of clopidogrel-based therapy.
4.1. Study Limitations. A major limitation of this study is
the restricted number of investigated patients. However,
the simultaneous evaluation of inflammatory mediators and
oxidative stress molecules in the bloodstream, over time dur-
ing therapy, associatedwith the analysis of the platelet protein
profile of ACS patients who differently respond to clopido-
grel, makes it possible to provide an overview of the main
modulated players in high RPR on clopidogrel therapy.More-
over, aspirin resistance and the relationshipwith high RPR on
clopidogrel were not assessed and need further investigation.
5. Conclusions
The upregulation of circulating and platelet adhesion
molecules and the presence of a defective platelet antioxidant
system suggest that oxidative stress and inflammatory signals
might favor platelet hyperactivity, which may be associated
with clopidogrel response variability. Proinflammatory
milieu persists in NR patients even at a late stage after the
acute event, while the antioxidant molecules tend to conform
to that of patients with normal responsiveness. An unbalance
of inflammation and oxidation markers is not unexpected
in the acute phase but follow-up evaluation evidences differ-
ential time-course between responders and nonresponders.
A phenotypic fingerprint associated with high RPR in
clopidogrel treatment is evidenced suggesting additional
factors that might be potentially exploited as clinically useful
predictors of resistance-related poststent complications.
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